Wintermute Biomedical presented ZosterEase clinical trial results at Asia Bio Partnering Forum, connecting with pharmaceutical, biotechnology and investment leaders from across the Asia-Pacific region.
This 50th Workshop also gives us the opportunity to reflect on the progress of our field, to honor the contributions of those who built this community, and to chart the path forward for the next generation of herpesvirologists.
Wintermute Biomedical joined the global biotechnology community at BIO 2026, connecting with pharmaceutical companies, investors and industry partners to advance the development and commercialisation of Solexan.
Wintermute Biomedical participated in BIO-Europe 2025, connecting with pharmaceutical, biotechnology and investment leaders to advance international partnering opportunities for Solexan.
Wintermute Biomedical returned to BioJapan in 2025, strengthening relationships across the Japanese and Asia-Pacific pharmaceutical sectors and progressing international partnering discussions for Solexan.
Wintermute Biomedical Chief Scientific Officer Dr Alyce Mayfosh presented Phase Ib clinical results for Solexan™ at the EADV Congress 2025, sharing findings from Wintermute’s first-in-patient shingles study with the international dermatology community.
Wintermute Biomedical presented Solexan™ to the global biotechnology community at BIO 2025, showcasing our novel topical antiviral and its potential as a new treatment option for herpes zoster (shingles).
Wintermute Biomedical participated in BioJapan 2024, engaging with pharmaceutical and biotechnology organisations and developing new relationships across Japan and the broader Asia-Pacific life sciences sector.
Wintermute Biomedical participated in BioTrinity 2024, connecting with European biotechnology, pharmaceutical and investment leaders and introducing the Solexan development programme to potential international partners.
